
|Articles|August 28, 2012
PODCAST: Dr. Goldfischer on OAB
PODCAST Efficacy and safety study comparing Oxybutynin 3% topical gel vs. placebo in adults with Overactive Bladder Syndrome.
Advertisement
PODCAST: Dr. Goldfischer on OAB
Efficacy and safety study comparing Oxybutynin 3% topical gel vs. placebo in adults with Overactive Bladder Syndrome.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study progresses of nogapendekin alfa inbakicept for BCG-naïve NMIBC
2
Practical uses of AI across the urologic care continuum
3
CREST and POTOMAC: Redefining immunotherapy’s role in NMIBC
4
Iman Sadri, MD, discusses novel nerve grafting strategy for erectile dysfunction after prostatectomy
5



















